Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Top Cited Papers
- 1 February 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 65 (2) , 157-170
Abstract
Objectives: The frontline drug doxorubicin has been used for treating cancer for over 30 years. While providing a cure in select cases, doxorubicin causes toxicity to most major organs, especially life-threatening cardiotoxicity, which forces the treatment to become dose-limiting.Key findings: Doxorubicin is known to bind to DNA-associated enzymes, intercalate with DNA base pairs, and target multiple molecular targets to produce a range of cytotoxic effects. For instance, it causes the activation of various molecular signals from AMPK (AMP-activated protein kinase inducing apoptosis) to influence the Bcl-2/Bax apoptosis pathway. By altering the Bcl-2/Bax ratio, downstream activation of different caspases can occur resulting in apoptosis. Doxorubicin also induces apoptosis and necrosis in healthy tissue causing toxicity in the brain, liver, kidney and heart. Over the years, many studies have been conducted to devise a drug delivery system that would eliminate these adverse affects including liposomes, hydrogel and nanoparticulate systems, and we highlight the pros and cons of these drug delivery systems.Summary: Overall the future for the continued use of doxorubicin clinically against cancer looks set to be prolonged, provided certain enhancements as listed above are made to its chemistry, delivery and toxicity. Increased efficacy depends on these three aims being met satisfactorily as discussed in turn in this review.Keywords
This publication has 77 references indexed in Scilit:
- Mechanism of anthracycline-mediated down-regulation of GATA4 in the heartCardiovascular Research, 2010
- Doxorubicin CardiomyopathyCardiology, 2009
- The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesisProceedings of the National Academy of Sciences, 2009
- ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- AMP-activated Protein Kinase Contributes to UV- and H2O2-induced Apoptosis in Human Skin KeratinocytesJournal of Biological Chemistry, 2008
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- A role for ceramide in driving cancer cell resistance to doxorubicinThe FASEB Journal, 2008
- Oncogenes and CancerNew England Journal of Medicine, 2008
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999